<DOC>
	<DOCNO>NCT02124044</DOCNO>
	<brief_summary>Chronic hepatitis C virus ( HCV ) infection major public health problem estimate 180 million people infected worldwide . In United States estimate 4.1 million people infected HCV principal cause death liver disease lead indication liver transplantation . Within HIV/HCV co-infected patient , liver disease due Hepatitis C progress even rapidly . While combination ribavirin ( RBV ) pegylated interferon ( PEG ) combination boceprevir/telaprevir currently recommend therapy chronic HCV infection superior cure rate compare PEG+RBV alone HCV monoinfected patient , treatment still associate high incidence adverse event ( AEs ) , discontinuation poor cure rate several population . Within HIV/HCV co-infected population treatment HCV remain complicated give drug interaction anti-retrovirals HCV protease inhibitor , addition extensive side-effects due PEG +RBV alone . Recent study demonstrate use combination anti-virals target HCV without interferon ( IFN ) cure HCV , without additional toxicity . These novel therapy rely IFN backbone may additionally enhance cure rate HIV/HCV co-infected , population historically difficult cure . This open label study ass safety , tolerability efficacy asunaprevir ( ASV ) 100 mg BID daclatasvir ( DCV ) 60 mg daily ( selective HCV NS3 NS5A inhibitor respectively ) 20 HIV/HCV co-infected treatment-na ( SqrRoot ) treatment experience HCV genotype 1b individual . The finding study aid understand antiviral host response determinant response IFN free regimen HIV/HCV co-infected patient .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Asunaprevir Daclatasvir Subjects Coinfected With HIV-HCV</brief_title>
	<detailed_description>Chronic hepatitis C virus ( HCV ) infection major public health problem estimate 180 million people infected worldwide . In United States estimate 4.1 million people infected HCV principal cause death liver disease lead indication liver transplantation . Within HIV/HCV co-infected patient , liver disease due Hepatitis C progress even rapidly . While combination ribavirin ( RBV ) pegylated interferon ( PEG ) combination boceprevir/telaprevir currently recommend therapy chronic HCV infection superior cure rate compare PEG+RBV alone HCV monoinfected patient , treatment still associate high incidence adverse event ( AEs ) , discontinuation poor cure rate several population . Within HIV/HCV co-infected population treatment HCV remain complicated give drug interaction anti-retrovirals HCV protease inhibitor , addition extensive side-effects due PEG +RBV alone . Recent study demonstrate use combination anti-virals target HCV without interferon ( IFN ) cure HCV , without additional toxicity . These novel therapy rely IFN backbone may additionally enhance cure rate HIV/HCV co-infected , population historically difficult cure . This open label study ass safety , tolerability efficacy two regimen treatment HCV , asunaprevir ( ASV ) 100 mg BID daclatasvir ( DCV ) 60 mg daily ( selective HCV NS3 NS5A inhibitor respectively ) 10 HIV/HCV genotype 1b co-infected treatment-na ( SqrRoot ) treatment experienced individual DCV + ASV + BMS-791325 administer fix dose combination ( FDC ) pill 20 HIV/HCV GT 1a 1b coinfected treatment-na ( SqrRoot ) treatment experienced individual . The finding study aid understand antiviral host response determinant response IFN free regimen HIV/HCV co-infected patient .</detailed_description>
	<criteria>INCLUSION CRITERIA Subjects meet follow criterion eligible enter study : 1 . Eighteen year age old screen 2 . Na ( SqrRoot ) treatment hepatitis C treatment experience previous IFNcontaining treatment chronic HCV infection . Patients reinfected HCV exclude . 3 . Women allow participate agree always use least two form birth control . One form must barrier protection ( i.e. , condom female condom ) meet one criterion : 1 . Nonchildbearing potential status ( i.e. , physiologically incapable become pregnant ) Has hysterectomy Has bilateral oophorectomy Is postmenopausal ( age great equal 50 demonstration total cessation menses great equal 1 year ) Has bilateral tubal ligation fallopian tube insert 2 . Childbearing potential status woman must negative serum pregnancy test screen agree use acceptable form birth control , follow : Complete abstinence sexual intercourse 2 week prior administration study drug completion followup procedure least 5 week ( woman ) last dose study drug . Vasectomized partner reliably monogamous relationship . An intrauterine device ( IUD ) 2 week prior administration study drug continuously completion followup procedure least 5 week last dose study drug . Double contraceptive method ( condom occlusive cap [ diaphragm cervical/vault cap ] ; spermicidal foam/gel/film/cream/suppository ) . Oral , implantable , transdermal , injectable form hormonal contraceptive NOT acceptable form contraception female study . 4 . Men allow participate agree use least 2 form birth control . One form must barrier protection ( i.e. , condom female condom ) meet one criterion : 1 . Are sterile 2 . Agree use least one follow approve method contraception 2 week prior administration study drug completion followup procedure least 14 week last dose study drug : A male condom spermicide . A sterile sexual partner . A female sexual partner IUD . A female sexual partner use female condom spermicide , intravaginal system ( e.g. , NuvaRing [ register ] ) , diaphragm spermicide , cervical cap spermicide , oral , implantable , transdermal , injectable contraceptive . 5 . Chronic GT1b ( 2DAA arm ) Chronic GT 1 ( 1a 1b ) ( 3DAA arm ) infection document one measurement serum HCV RNA great equal 2,000 IU/mL screen least one following : 1 . A positive antiHCV antibody , HCV RNA , HCV genotype test result great equal 12 month prior baseline ( Day 0 ) visit together current positive HCV RNA antiHCV antibody test result . Or b . Positive HCV RNA test antiHCV antibody test result together liver biopsy consistent chronic HCV infection liver biopsy perform Day 0 evidence chronic hepatitis C infection disease , presence fibrosis . 6 . HIV treatment status : 1 . Documented HIV infection ( define positive Western blot result detectable HIV viral load ) , ARV untreated &gt; 8 week precede dose either : 1 . A CD4 Tcell count great equal 500 cells/mm3 within 8 week Day 0 2 . An HIV viral load le 500 copies/mL stable CD4 count least 3 month 2 . Documented HIV1 ( define positive western blot result detectable HIV viral load ) infection stable protocolapproved , ARV regimen great equal 4 week prior dose expect continue current ARV regimen end study follow 1. CD4 Tcell count &gt; 100 cells/mm3 2. document plasma HIV1 RNA level less level detection measure least twice 4 week precede dosing . If low limit detection local HIV1 RNA result &gt; 50 copies/mL ( e.g. , &lt; 70 copies/mL , screen plasma HIV1 RNA level exceed 50 copies/mL ) . 3 . HIV ARV agent include : a. Raltegrativir plus one follow b. Tenofovir emtricitabine abacavir lamivudine 7 . Documentation hepatitis C genotype 1b ( 2DAA arm ) GT 1 ( 1a 1b ) ( 3DAA arm ) alone infection within 6 month prior Day 0 . HCV genotype/subtypes perform outside NIH accept eligibility perform use Siemens LiPA v2.0 assay assay equivalent performance identify HCV genetype 1b ( e.g. , Abbott RealTime HCV Genotype II assay ) . 8 . Liver biopsy obtain within 36 calendar month prior baseline ( Day 0 ) visit verify presence absence cirrhosis , except indicate . If recent ( &lt; 36 month ) liver biopsy available , liver biopsy may perform prior baseline visit . 1 . Cirrhosis define one following : 1 . Any biopsy showing cirrhosis ( time , restrict 36 calendar month prior baseline visit ) . 2 . A FibroSUR [ trademark ] score , &gt; 0.75 aspartate aminotransferase ( AST ) platelet ratio index ( APRI ) &gt; 2 within last year . 2 . Absence cirrhosis define one following : 1 . A liver biopsy perform within 36 calendar month screen show absence cirrhosis . 2 . A FibroSUR [ trademark ] score , within last year , &lt; 0.48 APRI &lt; 1 . In absence definitive diagnosis presence absence cirrhosis criterion detail , liver biopsy require . The FibroSURE [ trademark ] test perform result used determine inclusion exclusion criterion . Patients Child Pugh B C cirrhotics exclude 9 . Ability communicate effectively study investigator key personnel . 10 . Willingness comply study restriction requirement . 11 . Opioiddependent individual must participate supervised treatment program . 12 . Subjects must external primary care doctor ( outside Clinical Center NIH ) medical management . 13 . Willingness blood tissue sample store future use study liver disease immune function . 14 . Willingness undergo HLA typing . 15 . Otherwise healthy status determine medical history , physical examination , electrocardiogram ( ECG ) , clinical laboratory measurement perform screen . Contraception The effect ASV DCV develop human fetus unknown . For reason , men woman childbearing potential must agree use adequate contraception outline inclusion exclusion criterion prior study entry 5 week ( woman ) 14 week ( men ) last dose study medication . Hormonal contraception NOT consider effective form birth control female subject study . Oral contraceptive effective woman take ASV DCV woman rely form birth control prevent pregnancy . Females childbearingage must negative pregnancy test result prior receive ASV DCV . If woman become pregnant suspect pregnant course study , inform study staff primary care physician immediately . EXCLUSION CRITERIA 1 . Current prior history follow : 1 . Clinically significant illness ( HCV ) major medical disorder may interfere subject treatment , assessment compliance protocol ; subject currently evaluation clinicallysignificant illness ( HCV ) also exclude 2 . Gastrointestinal disorder postoperative condition could interfere absorption study drug 3 . Poor venous access interfering require study blood collection 4 . Clinical hepatic decompensation ( i.e. , ascites , encephalopathy variceal hemorrhage ) 5 . Hepatic impairment ( e.g. , ChildPugh class B [ moderate ] ChildPugh class C [ severe ] ) 6 . Solid organ transplantation 7 . Significant pulmonary disease , significant cardiac disease porphyria . 8 . Unstable psychiatric disease ( subject psychiatric illness well control stable treatment regimen currently require medication may include ) 9 . Any malignancy treatment opinion PI may cause ongoing interference host immunity ; subject evaluation malignancy eligible 10 . Significant drug allergy ( anaphylaxis hepatotoxicity ) 11 . Chronic liver disease nonHCV etiology ( e.g. , hemochromatosis , Wilson disease , alfa1 antitrypsin deficiency , cholangitis ) 2 . Positive nucleotide sequence analysis NS5A gene Y93H L31M/V polymorphisms 2DAA arm . 3 . Positive test result screen hepatitis B virus ( HBV ) surface antigen ( HBsAg ) HBV RNA ( complete necessary rule chronic HBV ) 4 . Current use nonprotocol approve ARVs 5 . A new AIDSdefining condition diagnose within 30 day prior date screen consent sign active serious infection ( HIV HCV ) , require parenteral antibiotic , antiviral antifungal within 30 day prior Day 0 6 . Abnormal hematological biochemical parameter screen , unless test repeat least one subsequent result within acceptable range prior study drug administration , include : 1 . Neutrophil count &lt; 750 cells/mm3 2 . Hemoglobin level &lt; 9 g/dL 3 . Platelet count less equal 50,000 cells/mm3 4 . Estimated glomerular filtration rate , calculate chronic kidney disease epidemiology collaboration formula : &lt; 50 mL/min/1.73 m^2 5 . ALT AST level great equal to10 time upper limit normal ( ULN ) 6 . Serum lipase level great equal 1.5 time ULN screen screen period patient symptom pancreatitis 7 . Total bilirubin level great equal 2.0 time ULN , except subject Gilbert syndrome 8 . Albumin level less equal 3.0 g/dL 7 . Donation loss blood &gt; 400 mL within 8 week prior first dose study drug 8 . Poorly control diabetes indicate screen glycosylated hemoglobin ( HbA1c ) &gt; 10 9 . Known hypersensitivity ASV , DCV formulation excipients 10 . Pregnant breastfeed 11 . Screening baseline clinically significant ECG finding , personal/first degree relative history Torsade de point 12 . Need use follow medication 21 day prior start study drug end treatment : 1 . Hematologic stimulate agent , erythropoiesis stimulate agent ( ESAs ) , granulocyte colony stimulate factor ( GCSF ) , thrombopoeitin ( TPO ) mimetics 2 . Chronic systemic antineoplastic immunomodulatory treatment include supraphysiologic dos immunosuppressant corticosteroid ( e.g. , prednisone equivalent &gt; 10 mg/day &gt; 2 week ) , azathioprine monoclonal antibody ( e.g. , infliximab ) 3 . Investigational agent device indication 13 Previous treatment HCV protease inhibitor DAA 14 . Medications disease condition exclude protocol ( e.g. , active cancer , transplantation ) list Concomitant medication section , disallow study 15 . Use certain medication herbal/natural supplement per PI discretion , expect result increase decrease exposure study nonstudy medication list Section 5.5 receving study medication within five halflives 14 day [ whichever longer ] first dose study medication . 16 . Coenrollment Guidelines : Coenrollment clinical trial restrict , enrollment observational study evaluate use licensed medication . Study staff notify coenrollment status , may require prior approval investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Coinfection</keyword>
	<keyword>HCV Genotype 1b</keyword>
	<keyword>Interferon Free therapy</keyword>
	<keyword>Liver Biopsy</keyword>
	<keyword>Virological Response</keyword>
</DOC>